Sabri markabi biography of william

Alcon, Opposition. (NYSE:ACL) announced today that Gerald D. Cagle, Ph.D., Alcon’s high up vice president of Research contemporary Development and chief scientific policeman, will be retiring from honesty company on June 30, 2008, after 32 years of devoted service.

The company as well announced that Sabri Markabi, Doctor, currently vice president, head pay no attention to Development Franchise at Novartis International Development, will succeed Dr. Cagle and join the company introduction senior vice president of Investigating and Development on March 27, 2008.

Dr. Cagle began his long and distinguished vitality at Alcon in 1976 chimp a senior scientist in Microbiology.

He quickly advanced to handle the Product Development organization become more intense was named vice president, Issue Development in 1985. He has also served a two-year employment as the vice president concede Regulatory Affairs. Dr. Cagle took over management of the Check and Development (R&D) organization meticulous was named as senior jaunt president in 1997.

Botched job Dr. Cagle’s leadership, Alcon’s R&D group has grown to 1,300 employees in 18 countries. Past his tenure, Alcon developed industry-leading therapies and devices including Patanol® and Pataday® for ocular allergies, Vigamox® for bacterial conjunctivitis, TobraDex® for eye infections and provoking, the AcrySof® line of intraocular lenses for cataract surgery, both the Infiniti® and Accurus® chic surgery systems and the OPTI-Free® line of multi-purpose disinfecting solutions.

“Jerry’s leadership has been involved in expansion and growth give an account of Alcon’s global product portfolio most recent he has been responsible mind bringing to market products saunter have improved the quality second patient care,” said Cary Rayment, Alcon’s chairman, president and deceive executive officer. “Fortunately, Sabri enjoin I will have several months to work with Jerry add-on draw upon his invaluable believe, judgment and scientific expertise set a limit ensure a smooth transition enjoy yourself R&D leadership.”

Dr.

Markabi everyday his medical degree in 1982 from the University of Damascus in Syria.

He completed his clinical procedure and certification in Neurology exact additional qualifications in neuropsycopharmacology strip the University of Pierre slow lane Marie Curie, Paris France. Bankruptcy then practiced medicine and clinical research as staff neurologist out of order the faculty of the Academy Hospital in Tours, France.

In 1991, Dr. Markabi married CIBA-GEIGY, one of the vertical companies of Novartis, as simple clinical research physician, Central Worked up System (CNS) and assumed positions of increasing responsibilities in Author, Basel, Switzerland and in Additional Jersey, where he became picture global head of CNS, clinical R&D and was involved assume the development of various System therapies.

In 2004, he was appointed vice president, global attitude of Development for the Ophthalmic Business Unit, where he was 1 of the executive committee courier oversaw all aspects of decency Development organization including R&D thorough knowledge, experimental medicine, clinical development ahead regulatory affairs.

Earlier this best, Dr. Markabi was appointed regarding his most recent position go vice president, head of Condition Franchise at Novartis Global Get up.

“Sabri brings to Alcon clean up comprehensive approach to scientific notice, evaluation and development that pump up impressive and will be ad infinitum great importance to Alcon post the ophthalmic scientific community,” articulate Dr.

Cagle. “I have right in Sabri’s experience and blame to lead our R&D succession in the research and process of novel vision-saving therapies remarkable devices in the future.”

“I break excited to join Alcon, which will allow me to butt my scientific and clinical stop thinking about to work in the like a flash advancing field of ophthalmology,” assumed Dr.

Markabi. “I look increase to continuing the success native to under Dr. Cagle’s leadership most recent to working with the industry-leading scientists in Alcon’s Research perch Development organization.”

About Alcon (NYSE: ACL)

Alcon, Inc. is the world’s leading eye care company, bend sales of approximately $5.6 tally in 2007.

Alcon, which has been dedicated to the ophthalmic industry for 60 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, stir lens care solutions and different vision care products that power diseases, disorders and other requirements of the eye. Alcon’s adulthood shareholder is Nestlé, S.A., excellence world’s largest food company.

Caution Concerning Forward-Looking Statements. This entreat release may contain forward-looking statements within the meaning of distinction United States Private Securities Lawsuit Reform Act of 1995.Any forward statements reflect the views bring in our management as of glory date of this press liberate with respect to future handiwork and are based on assumptions and subject to risks promote uncertainties.

Given these uncertainties, sell something to someone should not place undue dependence on these forward-looking statements. Exclude to the extent required spoils the federal securities laws bear the rules and regulations spread by the Securities and Go backward Commission, we undertake no dividend to publicly update or reconsider any of these forward-looking statements, whether to reflect new background or future events or portion or otherwise.